Last reviewed · How we verify
20μg Kangtai hepatitis B vaccine
20μg Kangtai hepatitis B vaccine is a Biologic drug developed by Wu Jiang. It is currently in Phase 1 development.
At a glance
| Generic name | 20μg Kangtai hepatitis B vaccine |
|---|---|
| Sponsor | Wu Jiang |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study on New Strategies for Hepatitis B Virus Immunization (NA)
- A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 20μg Kangtai hepatitis B vaccine CI brief — competitive landscape report
- 20μg Kangtai hepatitis B vaccine updates RSS · CI watch RSS
- Wu Jiang portfolio CI
Frequently asked questions about 20μg Kangtai hepatitis B vaccine
What is 20μg Kangtai hepatitis B vaccine?
20μg Kangtai hepatitis B vaccine is a Biologic drug developed by Wu Jiang.
Who makes 20μg Kangtai hepatitis B vaccine?
20μg Kangtai hepatitis B vaccine is developed by Wu Jiang (see full Wu Jiang pipeline at /company/wu-jiang).
What development phase is 20μg Kangtai hepatitis B vaccine in?
20μg Kangtai hepatitis B vaccine is in Phase 1.
Related
- Manufacturer: Wu Jiang — full pipeline
- Compare: 20μg Kangtai hepatitis B vaccine vs similar drugs
- Pricing: 20μg Kangtai hepatitis B vaccine cost, discount & access